In recent years, the most talked-about drugs in medicine are not 'heart drugs' or 'cancer drugs.' They are GLP-1 drugs: Ozempic, Wegovy, Mounjaro, and others. They were originally developed for type 2 diabetes, became famous as powerful weight-loss drugs, and for a long time were accompanied by great hope: perhaps they also protect the brain.
This was one of the most intriguing hypotheses in neurology. But science has progressed, and in the last two years, results from large controlled trials have accumulated, and they are much less impressive than hoped. Instead of a breakthrough story, what emerges is a mixed picture: promising early signals that did not withstand the decisive trials. It is worth understanding exactly what was found, and what was not.
What is GLP-1?
GLP-1 stands for Glucagon-Like Peptide-1, a natural hormone secreted by the gut after a meal. Its functions:
- Stimulating insulin production from the pancreas.
- Slowing gastric emptying (feeling of fullness).
- Reducing appetite.
- Helping regulate blood sugar.
GLP-1 drugs like semaglutide (brand names: Ozempic, Wegovy) and tirzepatide (Mounjaro) are engineered versions of this hormone, working longer and with greater potency. They are usually given as a weekly injection.
The Connection to the Brain: The Mechanism Hypothesis
What ignited the hope was a biological finding: GLP-1 receptors are not only found in the gut and pancreas, but also in the brain, including areas sensitive to neurodegeneration:
- Substantia nigra, the place where dopamine cells die in Parkinson's.
- Hippocampus, the memory area damaged in Alzheimer's.
- Motor neurons, damaged in motor neuron diseases.
In laboratory models and mice, activating these receptors has been linked to a series of possible protective mechanisms: reducing inflammation and nerve damage (less inflammatory microglial activation), improving mitochondrial function, activating autophagy (clearing damaged proteins like alpha-synuclein that accumulates in Parkinson's), and protection from excitotoxicity. It is important to emphasize: these are lab-based mechanism hypotheses. The real question is whether this works in humans, and there the picture is disappointing.
Parkinson's: Promising Signals, Decisive Trial Failed
Exenatide: Positive Phase 2 Trial, Negative Phase 3 Trial
In 2017, a small British trial was published in The Lancet (Athauda and colleagues, 62 participants) where exenatide showed modest motor improvement compared to placebo (a gap of about 3.5 points on the MDS-UPDRS Part III scale). This generated great excitement. But a small trial is only a hint, not proof.
The decisive trial was published in February 2025 in The Lancet: A Phase 3 trial involving 194 Parkinson's patients over 96 weeks. It failed. Exenatide did not slow the progression of motor symptoms compared to placebo, and showed no advantage in other measures of disease severity or quality of life. The researchers' conclusion was unequivocal: 'There is no evidence supporting exenatide as a disease-modifying treatment in Parkinson's.' This was the largest and longest trial to date, and it effectively closed the door on exenatide.
Lixisenatide: A Small Positive Signal, with a Price
The French LIXIPARK trial was published in the NEJM in April 2024: A Phase 2 trial in 156 early Parkinson's patients over 12 months. Here, a difference was found: after one year, the MDS-UPDRS Part III score was 14.9 in the lixisenatide group compared to 18.8 in the placebo group, meaning less motor deterioration in the drug group. But the difference was modest, and gastrointestinal side effects (nausea, vomiting) were common. This is a real but small positive signal that still requires confirmation in a larger trial.
Liraglutide: Improvement in Non-Motor Symptoms, Not Motor Skills
A trial from Cedars-Sinai Medical Center (63 participants, about 52 weeks) tested liraglutide in Parkinson's. The result: improvement in non-motor symptoms and daily functioning (ADL), but no significant slowing of motor deterioration. That is, the drug was well-tolerated and improved some aspects of quality of life, but did not stop the core of the disease. (For clarification: the 156-participant trial is the French lixisenatide trial, not the liraglutide one.)
Population Data: An Observational Signal Still Interesting
Alongside the controlled trials, large observational studies on databases of diabetes patients found that taking GLP-1 is associated with a 20% to 23% lower risk of developing Parkinson's compared to diabetes patients taking other drugs, as well as a lower risk of dementia. It is important to understand the difference: an observational study shows a correlation, not causation. It is possible that people taking GLP-1 differ in other ways (lifestyle, health status) that affect the outcome. The observational signal is interesting and warrants further research, but it is not a substitute for a controlled trial, and as we have seen, the controlled trials in Parkinson's disappointed.
Alzheimer's: The Large Trial Also Failed
There was also great hope in Alzheimer's, and here too the decisive trial disappointed:
- Observational studies showed a lower risk of dementia among GLP-1 users. This is, again, only an observational signal.
- In Alzheimer's mouse models, semaglutide and similar agents were linked to reduced beta-amyloid accumulation (a qualitative lab finding, not data that can be directly extrapolated to humans).
- The decisive trial, EVOKE and EVOKE+ by Novo Nordisk, failed. Two Phase 3 trials involving about 3,808 early Alzheimer's patients, whose results were published in November 2025, showed no significant slowing of disease progression (on the CDR-SB scale) compared to placebo. Interestingly: semaglutide did improve some biomarkers of the disease, but this did not translate into clinical benefit for patients. Novo Nordisk discontinued the extension periods of the trials.
This is a recurring lesson in brain medicine: Improvement in a lab biomarker does not guarantee clinical improvement in the patient.
So, Should You Take Ozempic for Brain Protection?
Based on current evidence, the answer is clear: No. The large controlled trials in Parkinson's and Alzheimer's failed, and GLP-1 is not a proven treatment for any of these neurodegenerative diseases. Furthermore, there are additional reasons for caution:
1. Significant Side Effects
- Nausea and vomiting, especially common at the start of treatment.
- Loss of muscle mass, part of the weight lost is muscle, which can be problematic in older adults.
- Pancreatic issues in rare cases.
- 'Ozempic face', loss of facial fat that accentuates an aged appearance.
2. No Known 'Anti-Aging' Dose
There are no data on long-term use of GLP-1 in healthy people as a preventive measure, and no known dose for this purpose.
3. High Cost
In Israel, without health basket coverage, semaglutide costs about 3,000 to 4,000 NIS per month.
4. No Long-Term Safety Data
The drugs have only been marketed for about seven years. There are no data on use for 20 to 30 years.
What Can You Take Away from This Story?
- If you have diabetes or obesity and need GLP-1 treatment for an approved medical reason, the decision is between you and your doctor. The observational signal regarding the brain is interesting, but it is an unproven 'possible bonus,' not a reason in itself.
- If you have a family risk of Parkinson's or early signs, talk to a neurologist, but do not expect GLP-1 to be the solution; the large trials failed.
- Maintain overall metabolic health. A Mediterranean diet, physical activity, and moderate fasting improve the body's natural metabolic signaling, and they have an independent and strong evidence base for brain health, without the side effects.
- Do not take a prescription drug on your own for 'brain protection.' There is no evidence base for this.
The Broader Perspective
The GLP-1 story is an excellent example of how real science works: A promising hypothesis, exciting early signals, and then the large trials rule, sometimes negatively. This is not a failure of science; it is its success. Controlled trials are precisely designed to filter hope from reality, and here they prevented patients from wasting money and time on a treatment that does not work.
What does remain on the table: the observational signal regarding a lower risk of Parkinson's and dementia among GLP-1 users continues to interest researchers, as does the idea of combination therapies. But until a controlled trial shows clear clinical benefit, GLP-1 remains an excellent drug for diabetes and obesity, and not a drug for brain protection.
The practical message for longevity remains what it was: Good metabolic health is linked to good brain health. Only the path to it, as of today, is through lifestyle, not through an injection.
References:
Exenatide Phase 3 (Exenatide-PD3), The Lancet, 2025
Lixisenatide in Early Parkinson's Disease (LIXIPARK), NEJM, 2024
EVOKE / EVOKE+ semaglutide Alzheimer's Phase 3, Novo Nordisk, 2025
💬 Comments (0)
Be the first to comment on the article.